Thyroid Cancer: Page 2

Popular rule-out test for thyroid cancer draws scrutiny

The researchers believe that their analysis of data from the Afirma GEC test (Veracyte) indicates the test may not live up to the results found in the pivotal trial used for the product's introduction (New England Journal of Medicine, August 23, 2012, Vol. 367:8, pp. 705-715). As a result, clinicians might want to recommend more aggressive follow-up of nodules classified as benign by the test.

July 18, 2019

Sonic touts ThyroSeq results at AACE 2019

ThyroSeq can help avoid diagnostic surgeries for suspected thyroid cancer by distinguishing between benign and cancerous nodules, according to the company. ThyroSeq testing has been expanded into cytology smears, which may be the only specimens available when a dedicated sample is not collected for molecular testing. With ThyroSeq, patients with indeterminate cytology won't have to make another visit to a physician's office to have another sample taken; instead, the available smears can be sent for testing.

April 28, 2019

Most Popular

Quest Diagnostics Q4 revenues down 15% on COVID testing but base business grew

In pilot study, liquid biopsy test differentiates between localized and metastatic cancer to inform tailored treatment

SD Biosensor, SJL Partners complete acquisition of Meridian Bioscience

Roche reports flat diagnostics revenue growth for 2022

French point-of-care testing firm Biosynex to acquire Chembio Diagnostics for $17.2M

OIG report outlines challenges with CDC-supported COVID-19 vaccination programs